Search

Your search keyword '"Castiglione F"' showing total 53 results
Start Over Author "Castiglione F" Journal digestive & liver disease
53 results on '"Castiglione F"'

4. T.05.2: REDUCING DIAGNOSTIC DELAY OF EXTRA-INTESTINAL MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A COMPARATIVE STUDY BETWEEN A MULTIDISCIPLINARY IMMUNE-MEDIATED DISEASES OUTPATIENT CLINIC AND CONVENTIONAL REFERRAL SPECIALISTS.

Author

Nardone, O.M., Calabrese, G., Peluso, R., Foglia, F., Megna, M., Cacciapuoti, S., La Mantia, A., D'Alessandro, E., Ferrante, M., Villani, G.D., Testa, A., Bonacci, L., Leo, C., Rispo, A., and Castiglione, F.

Published
2024
Full Text
View/download PDF

15. Increased risk of breast cancer in first-degree relatives of Crohn's disease patients: An IG-IBD study.

Author

Riegler, G., Caserta, L., Castiglione, F., Esposito, I., Valpiani, D., Annese, V., Zoli, G., Gionchetti, P., Viscido, A., Sturniolo, G.C., Rispo, A., De Filippo, F.R., de Leone, A., and Carratu, R.

Subjects
CANCER patients, INFLAMMATORY bowel diseases, CANCER susceptibility, BREAST cancer
Abstract

Abstract: Background: Increased rates of colorectal cancer have been reported in patients with ulcerative colitis as well as with Crohn''s colitis. This risk could be the result of shared genetic susceptibility and could be co-inherited rather than being just secondary to a long-standing, extensive mucosal inflammation. Aim.: To assess the prevalence of all malignancies in first-degree relatives of Crohn''s disease patients in order to establish whether any association exists. Patients and methods: A total of 632 outpatients with a diagnosis of Crohn''s disease and 632 control subjects were recruited. Information concerning the presence of malignancies was collected in 3292 first-degree relatives of Crohn''s disease patients and in 3303 first-degree relatives of controls. Results: Two hundred and fourteen (6.5%) subjects were found to be affected by malignancy in the first-degree relatives of Crohn''s disease patients and 180 (5.5%) in the first-degree relatives of controls. Forty-seven (7.4%) of Crohn''s disease patients had a first-degree relative with IBD, but none of them had cancer. The frequency of extra-intestinal malignancies was higher in first-degree relatives of Crohn''s disease patients than in those of controls (p =0.011). Frequency of breast cancer in female relatives of Crohn''s disease patients, mainly in mothers, was two-fold higher than that in controls (0.91% versus 0.42%; odds ratio=2.16; 95% confidence interval=1.14–4.08; p =0.015). The presence of breast cancer showed no association with any specific phenotype of disease in Crohn''s patients. Conclusions: These results did not corroborate the hypothesis about a common genetic susceptibility between Crohn''s disease and colorectal cancer. An unexpected finding was the more frequent occurrence of extra-digestive malignancies. The prevalence of breast cancer in first-degree relatives of Crohn''s disease patients, in particular the mothers, was more than double than in those of controls. This association, if confirmed, would suggest that there may exist common genetic and/or environmental factors for Crohn''s disease and breast cancer. [Copyright &y& Elsevier]

Published
2006
Full Text
View/download PDF

16. Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study.

Author

Orlando, A., Colombo, E., Kohn, A., Biancone, L., Rizzello, F., Viscido, A., Sostegni, R., Benazzato, L., Castiglione, F., Papi, C., Meucci, G., Riegler, G., Mocciaro, F., Cassinotti, A., Cosintino, R., Geremia, A., Morselli, C., Angelucci, E., Lavagna, A., and Rispo, A.

Subjects
FISTULA, HUMAN abnormalities, TUMORS, CYTOKINES
Abstract

Abstract: Background.: Almost 20% of patients with active Crohn''s disease are refractory to conventional therapy. Infliximab is a treatment of proven efficacy in this group of patients and it is not clear which variables predict a good response. Aims.: To evaluate the role of infliximab looking at the predictors of response in a large series of patients with Crohn''s disease. Patients and methods.: Five hundred and seventy-three patients with luminal refractory Crohn''s disease (Crohn''s Disease Activity Index (CDAI)>220–400) (312 patients) or with fistulising disease (190 patients) or both of them (71 patients) were treated with a dose of 5mg/kg in 12 Italian referral centres. The primary endpoints of the study were clinical response and clinical remission for luminal refractory and fistulising disease. We evaluated at univariable and multivariable analysis the following variables: number of infusions, sex, age at diagnosis, smoking habit, site of disease, previous surgery, extraintestinal manifestations and concomitant therapies, and type of fistulas. Results.: Patients with luminal refractory disease: 322 patients (84.1%) had a clinical response and 228 (59.5%) reached clinical remission. Patients with fistulising disease: 187 patients (72%) had a reduction of 50% of the number of fistulas and in 107 (41%) a total closure of fistulas was observed. For luminal disease, single infusion (OR 0.49, 95% CI 0.28–0.86) and previous surgery (OR 0.53, 95% CI 0.30–0.93) predicted a worse response for fistulising disease. Other fistulas responded worse than perianal fistulas (OR 0.57, 95% CI 0.303–1.097). Conclusion.: In Crohn''s disease infliximab is effective in luminal refractory and in fistulising disease. A single infusion and previous surgery predicted a worse response in luminal disease whereas perianal fistulas predicted a better response than other type of fistulas. [Copyright &y& Elsevier]

Published
2005
Full Text
View/download PDF

17. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.

Author

Caprilli, R., Angelucci, E., Cocco, A., Viscido, A., Annese, V., Ardizzone, S., Biancone, L., Castiglione, F., Cottone, M., Meucci, G., Paoluzi, P., Papi, C., Sturniolo, G.C., and Vecchi, M.

Subjects
INFLAMMATORY bowel diseases, IMMUNOSUPPRESSIVE agents, CROHN'S disease, ULCERATIVE colitis
Abstract

Abstract: Introduction.: Despite the explosion of biological therapies, the old immunosuppressants continue to play a pivotal role in the management of inflammatory bowel diseases. Aim.: To assess the appropriateness of immunosuppressants—azathioprine, 6-mercaptopurine, methotrexate, cyclosporine A, tacrolimus (FK506), mycophenolate mofetil and thalidomide—in the treatment of inflammatory bowel disease by using RAND/University of California Appropriateness Method. Methods.: The RAND method consists of a combination of evidence from the literature and experts’ opinions. Appropriateness has been defined to mean that the expected health benefit exceeds the expected negative consequences by a sufficiently wide margin. A panel of 10 experts from the Italian Group for Inflammatory Bowel Disease has rated, in two rounds, on a scale from 1 to 9, the appropriateness of each indication selected by the Promoter Centre, on the basis of their own clinical experience. An indication was considered appropriate if the median of the panelists’ ratings fell within the area 7–9, inappropriate in the area 1–3 and uncertain in the area 4–6. A total of 2781 indications were grouped into 13 categories (mild to moderate Crohn''s disease; severe Crohn''s disease; fistulizing Crohn''s disease; steroid-dependant and -resistant Crohn''s disease; maintenance of remission induced by medical treatment in Crohn''s disease; maintenance of remission induced by surgery in Crohn''s disease; mild to moderate ulcerative colitis; severe ulcerative colitis; steroid-dependant and -resistant ulcerative colitis; maintenance of remission induced by medical treatment in ulcerative colitis; extra-intestinal manifestations in inflammatory bowel disease; pregnancy and inflammatory bowel disease; azathioprine-resistant or -intolerant inflammatory bowel disease patients). Results.: Of the 2781 scenarios, 212 (7.6%) were rated appropriate, 645 (23.2%) uncertain and 1924 (69.2%) inappropriate. The most relevant results were: in steroid-dependant or -resistant Crohn''s disease, azathioprine, 6-mercaptopurine and methotrexate were defined as appropriate in 25 (86.2%) and 14 (48.3%) of the 29 scenarios respectively; in Crohn''s disease, azathioprine and 6-mercaptopurine were defined as appropriate combined with Infliximab (bridge therapy); in steroid-dependant or -resistant ulcerative colitis, azathioprine and 6-mercaptopurine were defined as appropriate in 45 (77.6%) out of 58 scenarios, while methotrexate was defined appropriate only after previous azathioprine failure; in severe ulcerative colitis, cyclosporine A was defined as appropriate only after previous failure with steroids; in azathioprine-intolerant or -resistant inflammatory bowel disease patients, methotrexate was appropriate in 20 (66.7%) out of 30 scenarios; it is inappropriate to stop azathioprine treatment before conception in the presence of active disease. The use of FK506, mycophenolate mofetil and Thalidomide resulted as inappropriate or uncertain. Conclusions.: Results of this study show that only azathioprine, 6-mercaptopurine and methotrexate are appropriate in the treatment of inflammatory bowel diseases. Cyclosporine A was found to be appropriate only in severe ulcerative colitis after the failure of steroids. FK506, mycophenolate mofetil and Thalidomide resulted as inappropriate but experience with these agents is somewhat limited. [Copyright &y& Elsevier]

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results